Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024. 

"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."

Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month. 

The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses. 

Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent. 

Share:
More In Business
The Most Important Job Skills Workers Should Know About
The World Economic Forum recently released its future of jobs report and broke down what abilities employers are looking for. Julia Pollak, chief labor economist at ZipRecruiter, joined Cheddar News to discuss what top, in-demand job skills are needed in the rapidly-changing economy.
What We Learned From Upfronts This Year Amid Writers' Strike
This year's upfront presentations to advertisers happened against the backdrop of a massive writers' strike. Cheddar News broke down the big takeaways from how networks proceeded with their events and what upcoming TV and streaming shows were presented.
Load More